Conduit Pharmaceuticals Inc. (CDT)
NASDAQ: CDT · Real-Time Price · USD
0.0747
+0.0091 (13.87%)
At close: Dec 20, 2024, 4:00 PM
0.0709
-0.0038 (-5.09%)
After-hours: Dec 20, 2024, 7:49 PM EST
Conduit Pharmaceuticals Employees
Conduit Pharmaceuticals had 7 employees as of December 31, 2023.
Employees
7
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,164,429
Market Cap
8.95M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Meihua International Medical Technologies | 617 |
| XWELL | 337 |
| Biofrontera | 85 |
| Mustang Bio | 80 |
| NeuroMetrix | 26 |
| Genprex | 26 |
| Soligenix | 15 |
| Cyclerion Therapeutics | 1 |
CDT News
- 9 days ago - Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics - GlobeNewsWire
- 4 weeks ago - Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders - GlobeNewsWire
- 4 weeks ago - Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors - GlobeNewsWire
- 6 weeks ago - Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline - GlobeNewsWire
- 7 weeks ago - Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes - GlobeNewsWire
- 4 months ago - Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders - GlobeNewsWire
- 4 months ago - Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments - GlobeNewsWire
- 7 months ago - AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024 - Business Wire